Clinical Trial

Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer

Study acronym: PRESELECT-0
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 2, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
About 70% of epithelial ovarian cancer patients are diagnosed at advanced stage. When primary optimal surgery is not possible, neoadjuvant chemotherapy will followed by interval debulking surgery is one treatment option. However, there is no consensus on the optimal timing of the surgery. CA125 is a well-known tumor marker in ovarian cancer. Its kinetic change has been proven to correlate with the patients' response to chemotherapy and chance of optimal resection. This study aims to utilize the kinetic change of CA125 to customize the timing of surgery for individual patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-06.
Trial Details
NCT Number NCT07022535
Lead Sponsor The University of Hong Kong
Conditions Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Enrollment 18 participants
Start Date 2024-05-28
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-02